BFM
CASC

Boothbay Fund Management’s Cascadian Therapeutics, Inc. CASC Stock Holding History

Boothbay Fund Management’s Portfolio CASC Stock Details CASC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-10,187
Closed -$42K – 959
2017
Q1 		$42K Buy
+10,187
New +$42.8K 0.01% 703

Other funds holding CASC

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PC
Polar Capital London, United Kingdom $13.5B AUM 55.9% 1-Year Est. Return
AFM
Anson Funds Management Dallas, Texas $2.29B AUM 370.24% 1-Year Est. Return

Boothbay Fund Management's CASC Position: Q2 2017 in Review

Boothbay Fund Management sold out of Cascadian Therapeutics, Inc. (CASC) in Q2 2017, closing a stake of 10,187 shares — an estimated $42K sold.

Boothbay Fund Management first reported a position in CASC in Q1 2017 and held it in 1 quarter. The position peaked at $42K in Q1 2017. 76 funds tracked by Wall St. Rank hold CASC as of Q2 2017.

  • Boothbay Fund Management reported no remaining Cascadian Therapeutics, Inc. position as of Q2 2017 after selling out during the quarter.
  • Boothbay Fund Management sold 10,187 Cascadian Therapeutics, Inc. shares in Q2 2017, an estimated $42K.
  • Boothbay Fund Management first reported a position in Cascadian Therapeutics, Inc. in Q1 2017 and held it in 1 quarter.
  • Boothbay Fund Management's Cascadian Therapeutics, Inc. position peaked at $42K in Q1 2017.
  • 76 funds tracked by Wall St. Rank held Cascadian Therapeutics, Inc. as of Q2 2017.

Based on Boothbay Fund Management's 13F filing for Q2 2017, filed 14 Aug 2017.